ClinicalTrials.gg
Not yet recruitingNCT07582601SWIC-BUpdated May 13, 2026

SWedish Intensive Care Biobank

An observational study in Any Condition Underlying Critical Illness, sponsored by Uppsala University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Primary conditionCritical Illness(the registry's first term)UnverifiedIs this wrong?Critical Illness is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Uppsala University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden. The main questions it aims to answer are:

Which genetic variants are associated with increased risk of critical illness from conditions such as infections, sepsis, and organ failure?

Can circulating proteins and metabolites mediate the effect of genetic risk factors on the severity of illness?

Participants will:

Provide blood samples at ICU admission and again 3-6 months after discharge Consent to genetic analysis and data linkage with national health registries

Have their ICU treatment and outcomes followed using registry and clinical data

This study aims to build a national infrastructure for rapid sample collection and analysis that can also support research in future pandemics.

02

Conditions studied

  • Any Condition Underlying Critical Illness

Keywords

  • critical illness
  • shock
  • sepsis
  • heart failure
  • ards
  • acute kidney injury
  • infection
  • organ failure
  • intensive care
03

In context

Critical Illness Unverified

1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.

This study's planned enrollment of 25,000 is above the median of 140 across 814 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Uppsala University is the lead sponsor of 390 studies on the registry; 86 are open to participants now.

Compared within Critical Illness, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patient admitted to intensive care at a hospital in Sweden

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults admitted to intensive care in Sweden

Exclusion criteria

Exclusion Criteria:

  • Non adults
  • Not admitted to intensive care
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • ICU admission

    Any patient admitted to ICU in Sweden

06

What researchers measure

Primary outcomes

  1. 30 day mortality

    Death of any cause within 30 days of ICU admission

    Time frame: 30 days

  2. ICU admission

    ICU admission for any specific cause

    Time frame: 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Swedish legal requirements preclude sharing individual patient data. Patient data access for collaborators is provided on a secure system.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07582601
Lead sponsor
Uppsala University
Responsible party
Michael Hultström (Associate professor, Uppsala University) — Principal investigator
First posted
May 13, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 30, 2035 (estimated)
Completion
Dec 30, 2035 (estimated)
Last update
May 13, 2026

Study contacts

Michael Marks-Hultström, MD PhD
Contact
michael.hultstrom@mcb.uu.se
0186110000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion